Ka testosterone maʻamau akā ke kiʻekiʻe o ka Luteinizing Hormone Level i nā kāne me ka Hypersexual Disorder (2020)

Introduction

Hypersexual maʻi (HD) kahi manaʻo e like me ka non-paraphilic moena moe makemake pili me ka hui pū ʻana o ka makemake a me ke ʻano o ka malehe ʻana o ka moe kolohe, ka hoʻohui ʻana, ka hoʻohālikule ʻana, a me ka hana paʻa.1 Ua manaʻo ʻia ʻo HD i kahi maʻi maʻi akā ʻaʻole i hoʻokomo ʻia ma ka Diagnostic and Statistical Manual of Mental Disorder 5, ʻo ia ka mea nui i nā hopohopo e pili ana i ka hōʻoia o ka hopena o ka hoʻomōlohelohe.2 Ma ke noiʻi ʻana i kākoʻo i ka hilinaʻi nui a me ka hōʻoia ʻana o nā ʻōlelo i manaʻo ʻia3 a ua ʻōlelo ʻia ka hoʻopiʻi.4 ʻO ke hōʻike hou ʻana i ka mea nui o ka maʻi lapaʻau ʻo nā hopena maikaʻi loa no ka olakino me ka ʻeha a me ka hana i hoʻopuhi ʻia no ke kanaka,1,5 a i kēia manawa, ua hoʻokomo ʻia ka hana moekolohe manuahi i loko o ka International Classification of Diseases-11 ma ka hui o nā mana kīnā lohi.6

He mea paʻakikī loa ka hoʻoponopono ʻana o ka moe kolohe me ka pūnaehana neuroendocrine, ka ʻōnaehana limu a me nā hopena papa o ka frontal lobe.7,8 Hoʻomaʻamaʻa ka testosterone a me ke ʻano moeʻuhane, akā he paʻakikī a ka pilina pololei a hoʻākāka ʻia nā ʻano like ʻole e wehewehe i nā hopena o ka testosterone e komo pū ana i ka ʻoluʻolu, nā manaʻo, nā pane autonomic, a me nā manaʻo.9 Ma ka laulaha, pili nā pae testosterone haʻahaʻa me ka hoʻemi o ka nui o nā hana moekolohe o ke kino a pili i ka pilina me nā moe kolohe e hiki ai ke hoʻololi, hoʻololi i nā pae o ka hormones sex.9,10 ʻO ka hapanui o nā haʻawina e pili ana i ka testosterone a me ke hypersexuality ua hana ʻia ma ka poʻe lawehala i nā pae forensic, a ʻo ka pae kiʻekiʻe o ka testosterone e hōʻike ʻia nei e pili ana i nā ʻano antisocial a me ka hoʻonāukiuki ma mua o ka hypersexuality.11 ʻOiai ka nele o ka ʻike e pili ana i ka hana gonadal ma ka moekolohe, he praxis maʻamau ia ma mua o 30 mau makahiki e hoʻohana ai i ka antiandrogen therapy e kuhikuhi i nā hōʻailona hypersexual i nā maʻi paraphilic a me nā lawehala kolohe.11,12 He mea nui ia e hoʻomaʻamaʻa i ka pilina ma waena o ka hypersexuality a me ka hana androgen, no ka mea nui ma ka testosterone i nā pae ʻole ʻole lawehala.

I ko mākou ʻike, ʻaʻohe i kēia manawa nā ʻike e pili ana i ka mana gonadal ma HD. ʻO ka pahuhopu o kēia noi ʻana e nānā i nā haʻahaʻa testosterone a me ka luteinizing kiʻekiʻe (LH) i nā kāne me HD me ka hoʻohālikelike ʻia me kahi pūʻulu mana o ka kāne i ke olakino olakino. ʻO ka pahuhopu lua, ʻo ia nō e ʻike i nā hui o ka epigenetic profile o hypothalamus pituitary adrenal (HPA) a me hypothalamus-pituitary-gonadal (HPG) –axis i hoʻopili ʻia nā pūnaewele CpG me nā pae testosterone a me LH.

Nā mea hana a me nāʻano

nā mea pono

Ua ʻae ʻia nā ʻōkuhi haʻawina e ka hui loiloi kūkala kūloko ma Stockholm (Dnr: 2013 / 1335-31 / 2), a hāʻawi nā poʻe ʻāpana i kā lākou ʻae ʻia i ʻae ʻia i ka ʻikepili ʻia.

Ka Heluhelu Kanaka

e hoomanawanui i

Ua loaʻa ʻia ka maʻi 67 o nā kāne me HD i ka Center for Andrology and Sexual Medicine, ma o ka hoʻolaha ʻana i nā hoʻolaha a me nā ʻōlelo i ka Center. Ua ʻimi ʻia nā mea maʻi i ka lāʻau lapaʻau a me / a i ʻole ka psychotherapeutic lapaʻau i hoʻolako ʻia ma hope o nā hoʻokolohua. Ua wehewehe ʻia ka heluna kanaka noiʻi i nā kikoʻī13 ʻO nā pae hoʻohālikelike kahi hōʻike o HD, ʻike pili pili, a me nā makahiki 18 a ʻoi paha. Ua hoʻokumu ʻia ke kuhi ma ka hoʻohana ʻana i ka Diagnostic a me ka Statistic Manual of Mental Disorder-5 – i nā pae hoʻohālikelike no HD, a pono i nā mea komo i ka 4 o ka 5 pae e hoʻokomo ai.4

Ua hoʻohana nui ʻia ka hui ahonui i ka porn (54 mau mea maʻi), masturbation (49 nā mea maʻi), ka hana me ka ʻelemakule (26 mau mea maʻi), a me ka cybersex (27 nā mea maʻi). ʻO ka hui pinepine e pili ana i ka masturbation a me nā kiʻi kiʻi (49 nā mea maʻi), ʻo ia ka mea a pau ka poʻe i hoʻohana i ka masturbation a hoʻohana pū kekahi i nā porn. Eia nō kekahi, 29 ka poʻe maʻi i loaʻa a he 3 a keu paha nā ʻano lawaiʻa.

ʻO ka hoʻomohala ʻana o ka maʻi HD a me nā ʻano noʻonoʻo ʻē aʻe i hoʻokumu ʻia e kekahi mau mea aʻoaʻo ua hoʻomaʻamaʻa ʻia a me ka ʻunikine lapaʻau e hoʻohana ana i ka ʻĀina Mini International Neuropsychiatric Interview.14 ʻO nā mea maʻi me ka maʻi psychotic o kēia manawa, ka waiʻona wai a me ka mea hōʻino o ka wai, nā maʻi psychiatric e koi hou aku i ka mālama ʻana e like me ke kaumaha nui me ka maʻi suicidal kiʻekiʻe, a me nā maʻi kino olakino e like me ka maʻi hepatic a i ʻole ke āpau.

Mau Paina Ola

39 ua loaʻa i nā mea hana olakino olakino no ke kikowaena ʻikepili Karolinska Trial Alliance (KTA). ʻO Karolinska Trial Alliance he kākoʻo kākoʻo i hoʻokumu ʻia e ka Pūnaewele ʻo Stockholm a me ka hale hoʻokumu ʻo Karolinska a me nā hana ma ke ʻano ʻo ka Center Clinical Research at Karolinska University Hospital e hoʻomaʻamaʻa i nā haʻawina ʻoihana maʻi. Ua hoʻokomo ʻia nā mea hana aku inā ua loaʻa iā lākou nei: ʻaʻohe maʻi kino koʻikoʻi, ʻaʻohe maʻi maʻi psychiatric mua a i ʻole, ʻaʻohe kūlana mua me ka schizophrenia, ka maʻi bipolar a i ʻole hoʻopau ʻia, ʻaʻole i hōʻike mua i nā trauma koʻikoʻi (nā pōʻino kūlohelohe a i ʻole he pepehi ʻia). Ua loiloi nā mea hana olakino me nā mea hana psychometric like like me nā kāne hypersexual. Ua hoʻokaʻawale ʻia nā mea ʻikepili pākuhi no ka maʻi pedophilic.

Mai ka huina o nā mea hana he 40 mau mea, ua hoʻokaʻawale ʻia kekahi ma muli o nā maʻi maʻi i ʻike ʻia mai nā hopena o ka laboratorium. Ua hoʻāʻo ʻia ka hana ʻana o nā mea hana olakino olakino i nā poʻe maʻi me ka HD a me ka manawa kikoʻī o ke kūleʻa koko e pili ana i ka pūnāwai a hāʻule paha i hana ʻia e hōʻemi ai i nā ʻano ʻano manawa.

Nānā

Ua noi ʻia nā mea noiʻi ʻē aʻe me nā mea i hana ʻia.

ka Hoʻolaha ninaninau ʻo Neuropsychiatric Mini (MINI 6.0) kahi hōʻoia, hōʻoia kino diagnostic i hoʻopaʻa ʻia no ka nānā ʻana i ka psychopathology ma ke koena I.14

ka ʻO ka papa helu hōʻike maʻi hōʻino hypersexual (HDSI) me nā mea 7 i ukali i nā pae hoʻohālikelike (5A a me 2B pae hoʻohālikelike) o HD. Loaʻa nā helu āpau mai ka 0 a i ka 28 me ka palena iki o 3 e pono ai ma ka 4 o ka 5 A-pae a me ka 3 a i ʻole nā ​​helu 4 ma ka palena iki o nā kaha B-1, no laila e pono ana ka helu kau palena iki he 15 no ka hōʻike o HD.3

ka Ka Hana HanaʻAna Hana Kānā (SCS) aia ka 10 o nā mea e pili ana i ka hana moʻo i ka moekolohe, ka hoʻokūkū pilikino, a me nā manaʻo a me nā moe kolohe ma ke ʻano he 4-point. Ua kūkulu ʻia ia no ka loiloi ʻana i ka lawena lawaiʻa kiʻekiʻe. Hōʻailona ka nui mai 10 a 40, he helu haʻahaʻa ma lalo o 18 e hōʻike ana i ka hōʻemi ʻana i ka moekolohe, 18–23 e hōʻike ana i ka moekolohe malewaliwali, 24–29 e hōʻike ana i ka maʻalahi, a ʻoi aku a i ʻole a he 30 a hōʻike ʻia i ke kiʻekiʻe o ka moekolohe.15

ka Hōʻailona Hypersexual: Scale Nā ʻImi Kūʻai ʻĀina (HD: CAS) ka loiloi ʻana i nā maʻi i hala 2 mau pule i mua o ke kipa hōʻike ʻana. ʻO HD: CAS he 7 mau nīnau me ka nīnau mua (A1) e noi ana i ke ʻano a me ka helu o ka moekolohe i hōʻike ʻia. ʻO kēia mau nīnau ʻeono (A6 – A2) e helu i kēia mau hōʻailona i ka manawa o 7 mau pule hou. Kuhi ʻia kēlā me kēlā me kēia nīnau (A2 – A2) ma ka 7-point kaha ākea (5–0) me nā helu he nui 4 0 i 24 mau hola.

ka Montgomery-Åsberg Pākuʻi Rating Rating Scale-self rating (MADRS-S) ka nānā ʻana i ka paʻakikī o ke kaumaha.16 Aia nā pālākiō helu 9 i nā nīnau depressive, i helu ʻia mai 0 a 6 mau helu me ka helu piha mai 0 a 54.

ka Nīnau Mīkini Trauma Pātikau (CTQ) no ka hana ʻana i nā maʻi trauma moʻolelo maoli he 28 mau helu loiloi a me 5 mau kāleka helu ana i ka nui o ka hōʻeha ʻana, ka hōʻino kino ʻana, ka hōʻino kino ʻana, a me ka haʻalele ʻana i ke kino. Loaʻa i kēlā me kēia subcale ma waena o 5 a 25 (ʻaʻohe mea i hōʻino ʻia).17

No nā kikoʻī e pili ana i nā hoa komo, e ʻoluʻolu Papa 1.

Papa 1Nā hiʻohiʻona maʻi o nā poʻe ʻikepili (me nā maʻi me ka maʻi hypersexual a me nā limahana olakino)
Nā hōʻailonaNā mea maʻi N = 67Nāʻaʻa ola olakino N = 39Nā ʻikepili (t-Hili, Kruskall-Wallis) P waiwai
Nā makahiki (mau makahiki)
 Mean39.237.5P = .45
 huahelu19-6521-62
 std11.511.9
ʻO ka hopohopo Diagnosisn = 11, 16.4%--
ʻO nā maʻi hopohopo Diagnosisn = 12, 17.9%--
Nā maʻi hoʻonaninanin = 1, (ADHD)--
Nā hōʻaihopihon = 11, 16.4%--
HDSI
 Mean19.61.6P <.001
 huahelu6-280-9
 std5.72.2
SCS
 Mean27.811.1P <.001
 huahelu12-3910-14
 std6.91.2
HD: CAS
 Mean10.30.38P <.001
 huahelu1-220-4
 std5.40.88
Nā ʻlelo nui
 Mean18.92.4P <.001
 huahelu1-500-12
 std9.72.9
Huina CTQ (n = 65)
 Mean39.9532.53P <.001
 huahelu25-8025-70
 std11.488.75

E nānā i ka papa i ka HTML

ADHD = nānā deficit hyperactivity maʻi; CTQ = nīnau pāpālua kamaliʻi; HD: CAS = maʻi maʻi hypersexual: pae kākela hōʻikeʻike; HDSI = hypersexual disorder screening inventory.

Ke Kūpono o ʻAle Hōʻī koko a me nā ʻAlama

Lawe ʻia nā laʻana koko āpau i ke kakahiaka ma kahi o 08.00 mau hola. Ua hana like ʻia ka laʻana koko no nā mea maʻi a me nā mea manawaleʻa olakino ma waena o ka pūnāwai a hāʻule ma waena o nā hui e hoʻoliʻiliʻi i nā ʻano kau o ka laʻana. Ua hana ʻia kahi hōʻike suppression dexamethasone me dexamethasone 0.5 mg me nā hopena i hōʻike ʻia ma mua.13 Ua kālailai ʻia ka pae o ka testosterone testosterone, LH, a me SHBG e ka electrochemiluminescence immunoassay COBAS (Roche, Basel, Switzerland) ma ke keʻena ʻo Chemical Clinical, Ke Haukapila Kula ʻo Karolinska, Huddinge. ʻO ka laulā ʻike testosterone testosterone he 0.087-52 nmol / L me nā coefficients intra-assay o ka loli (CVs) o 2.2% ma 3.0 nmol / L a me 2.0% ma 18.8 nmol / L a me CVs interassay o 4.7% ma 3.0 nmol / L 2.5% ma 18.8 nmol / L. ʻO ka laulā ʻike lH assay ʻo 0.1-200 E / L me nā CV intra-assay o 0.6% ma 4.0 E / L a me 0.6% ma 26 E / L a me nā CV interassay o 1.5% ma 4.0 E / L a me 2.0% ma 26 E / L. ʻO ka pae ʻike SHBG assay ka 0.35-200 nmol / L me nā CV intra-assay o 1.7% ma 17 nmol / L a me 2.2% ma 42 nmol / L a me nā CV interassay o 0.3% ma 17 nmol / L a me 0.9% ma 42 nmol / L. Ua ana ʻia ka hone stimulate Follicle (FSH) a me ka prolactin e like me ke ʻano o nā kiʻina hana ma ka hale hōʻikeʻike o ke Kulanui o Karolinska (www.karolinska.se).

Hoʻolololi ʻo Epigenetic

Ua hoʻopuka mua ʻia nā ʻike e pili ana i ka hoʻopili ʻana a ka methylation.18 No ka wehewehe ʻana i ka ʻike hoʻohālike, ka CpG kahua annotation, a me ke koho ʻana i ka HPA a me ka HPG axis-hoʻohui pili ʻana, e ʻoluʻolu e pili aku i Nā mea hou.

ʻIkeʻIke Heluhelu

Ua hoʻākāka ʻia nā helu helu helu helu āpau me ka hoʻohana ʻana i ka polokalamu Software Package JMP 12.1.0 (SAS Institute Inc, Cary, NC). Ka loiloi a me ka kurtosis o ka hoʻohele ʻana i nā loli mau e loiloi ʻia e ka hoʻokolohua Shapiro-Wilk. Ua hoʻokaʻawale ka pae o LH ma nā mea maʻi me HD a me nā mea hana olakino olakino, aʻo testosterone, SHBG, FSH, a me nā pae plasma prolactin ʻaʻole i kaawale i loko o nā limahana olakino a me nā maʻi, ma kēlā Haumana hemahema tUa hoʻohana ʻia ʻo Test a me Wilcoxon-Mann-Whitney e noiʻi i nā ʻokoʻa hui i nā loli mau ma waena o nā mea maʻi me HD a me nā mea kōkua manawaleʻa olakino. Ua hoʻohana ʻia nā loiloi kūpono e hoʻoholo ai i nā hui ma waena o nā loli a me nā biologic e like me ka nānā ʻana i nā mea hoʻohoka hewa. Ua hana ʻia nā hoʻāʻo o nā non-parametric a i ʻole parametric correlations me ka hoʻohana ʻana iā Spearman's rho a i ʻole Pearson's r. ʻO nā hoʻokolohua helu helu āpau he ʻelua huelo. ʻO ka P waiwai no ka nui mea <0.05.

Ua hana ka helu helu helu helu helu helu epigenetic ma ka hoʻohana ʻana ma R stat (The R Foundation for Statistical Computing, Vienna, Austria), version 3.3.0. Ma hope o nā hana hoʻomākaukau, ua hoʻomau ʻia nā koina he 87 i loko o ka kaohi ʻana ma hope o ka pae 221 HPA a me ka HPG axis-hoʻohui ʻia CpG. Ua hoʻohana ʻia ka hōʻike chi-kuahiwi e ʻike i nā ʻokoʻa i nā loli wae, no ka laʻana, ka wahine, ke kaumaha, a me ka hana hoʻokaumaha dexamethasone non-suppression. No nā covariates maikaʻi a me ka hoʻopaʻaʻana hui o ka epigenetic sample, e ʻoluʻolu Nā mea hou.

Results

Hōʻoia, LH, FSH, Prolactin, a me nā pae PlB SHBG i nā HD a me nā mea hoʻohālike olakino.

ʻOi aku ka nui o nā maʻi maʻi LH plasma kiʻekiʻe ma mua o nā mea hana olakino maikaʻi, akā ʻaʻohe ʻokoʻa iki ma waena o ka testosterone testosterone, FSH, prolactin, a me nā pae SHBG i nā mea maʻi me ka HD hoʻohālikelike ʻia me nā mea hoʻohua olakino, Hōʻike 1, Papa 2. Ua hoʻohālikelike maikaʻi ʻia ka testosterone me SHBG a me LH (r = 0.56, P <.0001; r = 0.33, P = .0005) i nā mea hoʻopaʻa haʻawina a pau. Ua mālama ʻia nā maʻi he 11 me nā antidepressants. ʻAʻohe ʻokoʻa nui ma nā pae plasma LH ma waena o nā mea maʻi e lawe ana a me nā mea maʻi i lawe ʻole i ka lāʻau.P = .7). ʻO nā mea maʻi e lawe ana i nā antidepressants i loaʻa nā pae plasma testosterone ʻoi aku ma mua o nā mea maʻi i mālama ʻole ʻia me ka antidepressant (P = .04).

 

E wehe i ke kiʻi nui

Hōʻike 1

Loaʻa ka LH (luteinizing hormone) plasma i ka maʻi hypersexual kāne a me nā kaola olakino.

Papa 2Hōʻike testosterone, LH, FSH, prolactin, a me nā kaila plasma SHBG i nā mea maʻi me ka maʻi hypersexual a me nā mea hoʻoikaika olakino.
Nā anaʻi EndocrineNā maʻi (N = 67) mean (SD)ʻO nā mea manawaleʻa olakino (N = 39) mean (SD)Nā ʻikepili (t-ʻo ka hoʻāāʻo, Wilikoki-Mann-Whitney) P waiwai
Kūlana (nmol / L)15.09 (4.49)14.34 (4.29).313
SHBG (nmol / L)32.59 (11.29)35.15 (13.79).6
LH (E / L)4.13 (1.57)3.57 (1.47).035 ∗
Prolactin (mIU / L)173.67 (71.16)185.21 (75.79).34
FSH (E / L)4.12 (2.49)4.24 (2.53).92

E nānā i ka papa i ka HTML

FSH = follicle stimulate hōmona; LH = luteinizing hōmona; SHBG, hōmona wahine – hoʻopaʻa paʻa globulin.

ʻĀpana ʻelua P-value <.05 ∗ i manaʻo nui ʻia.

Nā papa ʻaina haukapila a me nā pae Plasma Hormone

ʻO nā pilina ma waena o nā ana o ka moekolohe (SCS a me HD: CAS) a me nā pae plasma LH ʻaʻole nui. ʻO nā pilina o nā pae testosterone testosterone me nā ana o ka moekolohe (SCS a me HD: CAS) ʻaʻole mea nui i ka hui holoʻokoʻa (rho = 0.24, P = .06; r = 0.24, P = .05), Papa 3.

Papa 3Nā Aʻoaʻo (P nā waiwai), (Spearman rho lāua ʻo Pearson's r) ma waena o nā testosterone a me LH kūpaʻa a me nā loiloi lapaʻau i nā poʻe haumāna komo
Hoʻopau maikaʻi EndocrineCTQMAILS-SSCSHD: CAS
Testosterone0.0713 (0.5726)-0.0855 (0.4916)0.2354 (0.0551)*0.24 (0.0505) ∗
LH-0.1112 (0.3777)0.1220 (0.3253)-0.0078 (0.9501)-0.17 (0.1638)
SHBG-0.0179 (0.8877)-0.1421 (0.2514)0.1331 (0.2830)-0.04 (0.7703)

E nānā i ka papa i ka HTML

CTQ = nīnau nīnau trauma ʻōpio; HD: CAS = maʻi kolohe: ka pālākiō loiloi o kēia manawa; LH = luteinizing hōmona; MADRS-S = ka helu pālākiō helu helu pilikino Montgomery-Åsberg; SCS = pālua ka moekolohe compulsivity; SHBG = moekolohe wahine – paʻa globulin. ʻO ke kumu hoʻohālikelike ʻo Pearson r ua hoʻohana ʻia.

*P <.1.

Hoʻohui nui ʻia ka testosterone me SCS i nā mea maʻi me HD (rho = 0.28, P = .02). ʻAʻohe pilina koʻikoʻi ma waena o testosterone a me nā pae plasma LH, nā hōʻailona depressive i ana ʻia e MADRS a i ʻole CTQ mau helu, Papa 3.

Nā Nānā Pāʻani o nā ʻĀina Ma waena o 221 HPA a me HPG Axis-Hoʻopili i nā CpG Pūnaewele Me ka Hōʻike Testasma a me LH pae.

ʻAʻohe pūnaewele CpG koʻikoʻi ma hope o ka hoʻoponopono ʻana i ka hoʻāʻo ʻana no ka hoʻohana ʻana i nā ala hoʻokae hōʻike hewa ʻole, no nā kikoʻī, e kuhi Nā mea hou.

kūkākūkā

I loko o kēia noi ʻana, ua ʻike mākou ʻaʻohe ʻano ʻokoʻa o nā kāne kāne HD me nā pae testosterone testosterone i hoʻohālikelike ʻia me nā limahana limahana olakino. Ma ka ʻaoʻao ʻē aʻe, ʻoi aku ka kiʻekiʻe o kā lākou pae plasma ʻo LH. ʻO ka pae testosterone a me nā pae LH o nā hui ʻelua ma loko o ka pae kuhikuhi. I ko mākou ʻike, ʻo kēia ka hōʻike mua o ka HPG disregulation i nā kāne me HD. He kuleana nui ko LH i ka rula o ka moekolohe ma o ka hana like ʻana o androgens. ʻO nā haʻawina ma mua e pili ana i nā pae plasma LH a me ka hoʻāla ʻana i ka moekolohe i hāʻawi i nā hopena contradictory, kahi e wehewehe ʻia e kekahi mau ʻike kikoʻī e pili ana i ka LH pulsivity a me ka bioactivity. Stoleru et al19 ua hōʻike ʻo ka moe kolohe i ka wā'ōpio i ka hopena ma ka hōʻailona o ka LH pulse e hopena i ka hoʻopiʻi ʻana i ka lua o ka lua ma hope o ka hānai a hoʻonui i kona kiʻekiʻe.19 Maliʻa paha aia kekahi ʻokoʻa i ka lakio bioactive / immunoactive o LH. Carosa ma20 ua hōʻike ʻo ka poʻe maʻi me ka erectile dysfunction kahi nui haʻahaʻa o ka nui o ka bioactive / immunoactive ratio LH ma mua o nā kāne olakino, a ua hoʻihoʻi ʻia ma hope o ka hoʻomau ʻana o ka hana moekolohe.

ʻO ka hapa nui o nā noiʻi e pili ana i nā homone a me nā moekolohe kolohe i loko o kahi forensic e ʻimi nei i nā lawehala kolohe. Kingston ma21 Ua hōʻike maikaʻi ʻia nā homone gonadotrophic, FSH, a me LH me ka hoʻowahāwahā i nā lawehala kolohe a ʻoi aku ka wānana no ka recidivism wā lōʻihi ma mua o nā pae testosterone i kahi noiʻi e pili ana i nā lawehala kolohe a 20 mau makahiki. Ua hoʻopaʻapaʻa nā mea kākau i kekahi lawehala lawehala i kahi disregulation o LH me ka hoʻokō ʻole o ka downregulation kūʻokoʻa i kā lākou pae testosterone. Eia hou, i loko o kahi noiʻi e hoʻohālikelike ana i nā kāne me ka pedophilia a me nā non-pedophilic paraphilia, a me nā kaohi kāne maʻamau, ʻoiai ʻaʻohe ʻokoʻa i waena o nā hui i nā pae testosterone a me LH ma hope o ka hoʻokomo ʻia ʻana o 100 mcg o ka synthetic LH-hoʻokuʻu i ka hormone, ka pedophile ʻoi aku ka kiʻekiʻe o ka hui o LH, hoʻohālikelike ʻia me nā hui ʻē aʻe 2.22 He paʻakikī, e hiki ke kahakaha pono i waena o kēia mau ʻike i hōʻike ʻia ma nā pae forensic a me kā mākou ʻike e ʻike nei i nā kāne me HD me ka pedophilia a ʻaʻole hoʻi i ka mōʻaukala o ka moekolohe.

He paʻakikī nā pilina ma waena o ka wahine a me nā pae testosterone. ʻOiaʻiʻo, pili pono ka testosterone me ka wahine a me ka hōʻiliʻili wahine me ka hopena ma o nā ʻōnaehana he nui i nā hanana kognitive, nā manaʻo, nā hana autonomic, a me nā kumu holoʻokoʻa.9,10 Hiki i kēia mau hopena ke kūleʻa ʻole ma o ka hoʻololi ʻana i ka estradiol a me ka hoʻopili ʻana i nā mea i ʻae ʻia. Hoʻopilikia ka pae a me ka pae LH i ka moe kino a me ke ʻano. ʻO ka hoʻouluʻana i ka Erotic erotic, ʻo ka nui o nā orgasms ma o coitus a i ʻole masturbation, a me ka hoʻomakaʻana o ka launa pūʻana e hiki ke hoʻopilikia i nā pae testosterone.9,10 Eia kekahi, ke ʻano o ka hoʻoulu ʻana, ka ʻōlelo, a me nā ʻike o mua e hiki ke hoʻololi i kēia mau hopena i nā pae testosterone. Rupp a me Wallen23, ma ka noiʻi ʻana o nā kāne i hōʻike ʻia i ka erotica ʻike, ka hoʻopaʻi ʻana i ka pae o testosterone e ka ʻike, e hōʻike ana e pili ana nā pae testosterone e pili ana i ka makemake pilikino i ke kāne nānā i ke kiʻi ʻana i nā kiʻiʻoniʻoni a i nā kāne me ka ʻike maka mua o ka. ponokala ma mua o ke aʻo ʻana. Kuhi nā mea kākau e pono ai ka testosterone e hoʻonui i ka hoʻoikaika a me ka hana cognitive i ka wā kahi i noho ai ka habituation o ka mea hoʻokaumaha ma ka hōʻike mau.23 ʻOiai ʻaʻole ʻokoʻa nā pae testosterone ma waena o nā kāne me nā HD a me nā mana palekana, ʻo nā hoʻoponopono ma waena o nā testosterone plasma a me nā ana o ka hypersexuality e hōʻike ana i kahi kūlana koʻikoʻi ma ka hui holoʻokoʻa a me ka hopena koʻikoʻi maikaʻi i nā kāne me HD me ka pae kiʻekiʻe o testosterone ma ka poʻe maʻi e hōʻike ana. nā hana moekolohe hou aʻe, ka hana hoʻokalakupua, a me ka noʻonoʻo ponoʻole.

Eia nō naʻe, ua hōʻike ʻia nā haʻawina e pili ana i ka testosterone i ka lawehala e pili ana i nā hopena i hui ʻia, a ua hōʻike ʻia ka meta-analima no ke kākoʻo ʻana o ka hoʻololi ʻana i ke kiʻekiʻe o ka testosterone i ka poʻe hana hewa i hoʻohālikelike ʻia me nā mea hana hewa ʻole a he mau ʻokoʻa ʻē aʻe i loko o ka moekolohe ʻoiai he mau molesters keiki. ua loaʻa ka testosterone haʻahaʻa.24 Akā e pili ana i ka testosterone supplementation no ka hana moekolohe, kahi loiloi ʻōnaehana o nā hoʻokolohua hoʻokolohua kaulike ʻia e Huo et al25 hele mai i ka hopena, pili e pili ana i ka libido, ʻoiai ua ʻoi aku ka maikaʻi ma mua o nā loiloi maikaʻi ʻole, e hui pū nā hopena. Eia kekahi, ʻaʻole paʻa ka testosterone supplementation i ka hoʻomaikaʻi ʻana i ka hana pilikino. ʻO ka mea hope loa, ua hoʻomaʻamaʻa ka hapanui o nā noiʻi i ka hopena o ka testosterone a me LH ma hope o ka hopena o kahi hoʻoulu kūlohelohe kūlohelohe, no ka hoʻohālike ʻana, ka wahine male kiʻi, ka masturbation, a me ka coitus19 a ʻaʻole i noiʻi i nā hopena i ke koʻi HPG i kahi kūlana lōʻihi loa e like me nā mea maʻi me HD. No laila, ʻo ka loaʻa ʻana o nā mea like ʻole o ka pae testosterone i nā kāne hypersexual i hoʻohālikelike ʻia me nā mea hana olakino e pīhoihoi ana.

He nui wale nā ​​noiʻi e noiʻi ana i nā kāne hypersexual a me nā pūnaehana endocrine. Safarinejad26 ana i ka hopena ʻana i nā hopena lapaʻau lōʻihi o ka hoʻohālikelike lōʻihi o ka gonadotropin-hoʻokuʻu i ka hormone, triptorelin, i nā kāne non-paraphilic hypersexual i hōʻike i nā pae maʻamau o ka pae baseline testosterone a me LH pae, akā naʻe, ʻaʻole i hoʻonohonoho ʻia ka papa noiʻi ʻana i kahi pūʻulu mana olakino. Ma kēlā haʻawina, ʻo LH a me testosterone pae like a me ka hopena o ke kino (ka helu o nā hoʻonaninani) ʻo nā kāne hypersexual i hōʻemi me ka hana e hōʻike ana i ka pilina pili o ka pae o ka hormone a me ka wahine.

Ua pili pū ʻia nā pae testosterone e pili ana i ke kaumaha a me nā mea kaumaha i nā kāne hypogonadal.9,10 ʻAʻole i loaʻa iā mākou ka hopena koʻikoʻi ma waena o nā pae testosterone a me nā hōʻailona kaumaha. Hoʻokomo ʻia ka HD i kāna wehewehe ʻana i hiki ke lilo i ka hopena i hopena i nā wahi a dysphoric a me ke kaumaha,1 a ua hōʻike mua mākou i kahi maʻi lōkuhi me ka hyperactivity o ke koiʻi HPA13 e like me nā loli epigenetic e pili ana i nā kāne me HD.18

Aia nā hopena paʻakikī ma waena o ka HPA a me HPG axis, ʻelua excitatory a me ka pale ʻana i nā ʻokoʻa like ʻole e pili ana i ke ʻano o ka pae o ka lolo.27 ʻO nā hanana koʻikoʻi ma o nā hopena o nā koʻi ʻo ka HPA ka hopena i ka pale ʻana i ka hoʻomakeʻo LH a ma muli o ka hana hou.27 Loaʻa nā ʻōnaehana 2 i nā launa pānaʻi, a hiki i nā stressors mua ke hoʻololi i nā pane neuroendocrine ma o nā epigenetic hoʻololi.28, 29, 30

ʻO ka hoʻoponopono ʻana o ka pae testosterone testosterone me nā palena o ka hypersexuality (SCS a me HD: CAS) i ka hiʻohiʻona iki o ka hui holoʻokoʻa, a ua hoʻomaikaʻi maikaʻi ʻia ka testosterone me SCS i nā mea maʻi me HD. Hoʻopili ke SCS i nā hana moekolohe, moekolohe, a me ka noʻonoʻo pono i ka wahine a ua hoʻomohala ʻia no ka loiloi o nā ʻano moeʻuhane kiʻekiʻe.15 Hoʻokomo ʻia nā ʻano mea hana ole ma ke ʻano he mea pili i ka moekolohe me ka wahine like ʻole, ka nui o nā kāne, ʻoi aku ka moe kolohe, ka moe kolohe anal, loaʻa ʻole nā ​​maʻi, a me ka hoʻohana ʻana i ka lāʻau lapaʻau a me ka waiʻona ma mua o ka moekolohe.1,31 Hoʻomaʻamaʻa ka testosterone i ka lawe ʻana i ka hana a me ka cortisol, e like me ka hypothesis ʻelua pālua, hoʻololi lākou i ka lawe ʻana.32 Hoʻolālā kēia haʻano maʻi maʻi ʻelua e pili ana nā ʻano e pili ana i ke kūlana e like me ka hoʻonāukiuki a me ka lanakila i ka pilina me ka testosterone wale nō i ka wā i haʻahaʻa nā pae o cortisol akā ʻaʻole i ka wā i kiʻekiʻe nā kiʻekiʻe cortisol. Ma kēia lālani, ua hoʻolaha koke mākou nei i ka nui o ka CSF testosterone / cortisol ratio i hoʻomaikaʻi maikaʻi ʻia me ka impulsivity a me ka hana hoʻonāukiuki i loko o kahi pūʻulu hoʻāʻo e hoʻohana i ka pepehi kanaka.33 Eia kekahi, hoʻopilikia kino nā pae cortisol plasma me nā helu SCS i nā kāne me HD.13 No laila, ʻo ka hopena maikaʻi ʻole o nā pae cortisol me ka SCS a me ka hoʻoponopono maikaʻi ʻana o nā pae testosterone me ka SCS e kau ana me ka hypothesis he lua. He multifaceted like ka makemake i ka moekolohe, a me nā manaʻo e like me ke koʻikoʻi, ka wahine, a me ka makemake makemake e hoʻololi i nā hui e like me nā testosterone e like me testosterone.34,35 Kēia mau mea hana i ʻōlelo ʻia i loko o ka hoʻopili ʻo HPA a me HPG, ka ʻōnaehana neural uku, a i ʻole ka pale ʻana o ka hoʻoponopono o nā hoʻokele i nā wahi cortex mua.32

ʻO kahi wehewehe e koho ai, ʻo ia ka uku o ka hypogonadism uku, ka mea maʻamau me ka maʻamau a i ʻole nā ​​palena palena, pae kiʻekiʻe o ka testosterone, a kiʻekiʻe a i nā kiʻekiʻe kiʻekiʻe o nā pae o ka LH plasma a me kahi hana uku. Eia naʻe, pili ka compogatory hypogonadism e pili ana i ka holomua o ka makahiki a me nā comorbidities kūlohelohe, ʻaʻole e like me kā mākou tauira, ʻo ia ka makahiki i kūpono i ka hui kia hoʻokele a kūʻokoʻa mai nā comorbidities.

E pili ana i nā epigenomics, ua hoʻohana ʻia nā ʻāpana methylation ākea genome me nā pūnaewele ʻoi aku ma mua o 850 K CpG, akā ua nānā mākou i nā genes moho e pili ana i ka axis HPA e pili ana i kā mākou ʻike mua.18 a me nā ʻōnaehana maʻamau o HPG axis-pili a me nā ʻōnaehana i hōʻike ʻia e pili ana i nā ʻano moe kolohe e like me ka oxytocin a me kisspeptin.36, 37, 38

I nā helu hoʻohālikelike laina laina mua i nā pae testosterone testosterone, 12 mau pūnaewele CpG i nui mau inoa a me 20 mau pūnaewele CpG no nā pae LH plasma. ʻAʻohe pūnaewele CpG koʻikoʻi ma hope o ka hoʻoponopono ʻana i ka nui o ka hoʻāʻo ʻana. ʻO kēia ka haʻawina epigenetic mua o ka HPG axis-pili genes i HD, a ua hōʻike mua mākou i nā loli epigenetic ma nā ʻano huakaʻi HPAaxis-pili.18 Pono e wehewehe ʻia nā hopena maikaʻi me ka akahele. Ma muli o ka nui o ka pākuhi liʻiliʻi, he mea paʻakikī ke ʻike i nā hua liʻiliʻi liʻiliʻi, ʻoiai ma hope o ka hoʻoponopono ʻana i ka nui o ka hoʻāʻo ʻana.

ʻO nā ikaika o ke aʻo ʻana i koho ʻia me ka poʻe ʻōpiopio o ka hypersexual mākaʻikaʻi, ka hele ʻana o kahi pūʻulu mana e hoʻohālikelike ʻia i nā ʻōnaehana olakino, ke kaawale ʻana i ka mōʻaukala a i ʻole ka manawa maʻi psychiatric, mōʻaukala ʻohana o nā maʻi psychiatric nui, a me nā hanana traumatic koʻikoʻi. Eia kekahi, ʻo ka moʻoʻī no nā hūnā e hiki ai i nā ka nānā ʻana e like me ka pōʻino o ke wā kamaliʻi, nā kaumaha, nā mākaʻi neuroinflamothing, a me nā hopena hōʻike dexamethasone. ʻO nā palena e like me ka hōʻike ponoʻī ʻana i ka puʻu ʻana o ka wā kamaliʻi a me ka laʻana liʻiliʻi liʻiliʻi no ka epigenetic anal ʻana. ʻO kahi ikaika hou e hoʻohālikelike ana nā pakanā o ka methylation, a me nā hopena epigenetic maikaʻi ʻole i pili i ke kumu kiko (koko āpau). Eia kekahi, ʻo ka neʻe i ka hana moekolohe hiki ke lilo i kahi confounder e ka mālama ʻana i nā pae o ka hormone39 ʻoiai ʻaʻole mākou e kaohi no ka hana moekolohe hou loa. Eia nō naʻe, ʻaʻohe hui ma waena o nā pae hormonone a me nā hana moekolohe, i nā pule he 2 i hala, i ana ʻia me HD: CAS e hōʻike ana i kahi hopena. Eia kekahi, ua ana ʻia ka testosterone e kahi immunoassay ma mua o ka chromatography wai - nā ʻano spectrometry lehulehu.

ʻO ka mea hope loa, he palena palena ʻānō ia o ka hoʻopaʻa ʻana no ka ʻae ʻana i nā hopena, a he pono e hoʻokaʻina i kahi cohort kūʻokoʻa ʻo ia ka mea mua o ka loiloi mua o HPG axis a me epigenetics i HD.

I ka hopena, hōʻike mākou no ka manawa mua i hoʻonui nui i ka pae LH plasma i loko o nā kāne hypersexual i hoʻohālikelike ʻia me nā mea hana ikaika. Kuhi kēia mau ʻike mua i ka ulu ʻana i nā puke i ka pili ʻana o nā ʻōnaehana neuroendocrine a me ka disregulation ma HD.

Hiki ke ʻike ʻia nā kuhikuhi no nā noiʻi hou aʻe i ka HD. ʻO ka hapa nui o ka noiʻi ua hana ʻia i loko o nā kāne a ma nā lehulehu e like me nā lawehala e pili ana i ka wahine. No laila, ʻo nā hiʻohiʻona haukapila o nā wahine hypersexual, nā ʻokoʻa wahine, a me nā iwi o ka haukapila e nele ana nō. Pono e wehewehe ʻia nā comorbidities, ʻoiai me nā maʻi psychiatric ʻē aʻe e pili ana i ka waiwai a me ke ʻano hana. Hiki i kekahi ala ke aʻo i nā poʻe maʻi me ka maʻi kūlohelohe me ka HD / compulsive me ka ʻole o ka comorbidities. ʻO ka hopena hope loa, e makemake nui ʻia ka noi ʻana i nā palena palena ʻāina noiʻi. ʻO ka Neuroimaging, molekue, genetic, a me nā haʻawina epigenetic me ka hoʻohui pū ʻana i nā ʻano like e like me ka hōʻeha ʻana, ka impulsivity, a me ka hana antisocial e hoʻomaʻemaʻe i ka pathophysiology o ka hopena.

Ka'ōlelo o ka mea kākau

    Kūkākūkā o 1

  • (a) ʻeptionkuhi a me ka hoʻolālā ʻana

    • Andreas Chatzittofis; Adrian E. Boström; Katarina Görts Öberg; John N. Flanagan; Helgi B. Schiöth; Stefan Arver; ʻO Jussi Jokinen

  • (b) ka loaʻa ʻana o ka ʻike

    • Andreas Chatzittofis; John Flanagan; ʻO Katarina Görts Öberg

  • (c) Nānā a me ka wehewehe ʻana i ka ʻike

    • Andreas Chatzittofis; Adrian E. Boström; Helgi B. Schiöth; ʻO Jussi Jokinen

    Kūkākūkā o 2

  • (a) Ka hana ʻana i ka ʻatikala

    • Manuela Chatzittofis

  • (b) Ka nānā ʻana no ka ʻike ʻona

    • Andreas Chatzittofis; Adrian E. Boström; Katarina Görts Öberg; John N. Flanagan; Helgi B. Schiöth; Stefan Arver; ʻO Jussi Jokinen

    Kūkākūkā o 3

  • (a) Ka ʻae ʻae i ka ʻatikala i hoʻopau ʻia

    • Andreas Chatzittofis; Adrian E. Boström; Katarina Görts Öberg; John N. Flanagan; Helgi B. Schiöth; Stefan Arver; ʻO Jussi Jokinen

mau hoomaikai ana

Hana ʻia ka profylation profiling e ka SNP & SEQ Technology Platform ma Uppsala (www.paoohao.se). ʻO ke keʻena kahi ʻāpana o ka National Genomics Infrastructure (NGI) Suetena a me ʻEpekema no ke Keʻena Hoʻokolohua Ola. Kākoʻo ʻia ka SNP & SEQ Platform e ka Suetena ʻImi Suède a me ka Knut a me Alice Wallenberg Foundation.

Nāʻikepili

E hoʻomaopopo '

  1. Kafka, MP ʻO ka maʻi hypersexual: kahi maʻi noi noi no DSM-V. Hoʻopili i ka wahine Behav. 2010; 39: 377-400

    |

  2. Moser, C. ʻO ka maʻi maʻamau:ʻoi aku ka maikaʻi o ka noʻonoʻoʻana. Hoʻopili i ka wahine Behav. 2011; 40: 227-229

    |

  3. Reid, RC, Kahiki, BN, Hook, JN et al. Hōʻike hōʻike i nā hōʻike ma kahi hoʻokolokolo DSM-5 no ka maʻi hypersexual. ʻO J Sex Med. 2012; 9: 2868-2877

    |

  4. Kafka, MP He aha ka mea e kū ai i ka maʻi hypersexual ?. Hoʻopili i ka wahine Behav. 2014; 43: 1259-1261

    |

  5. Langstrom, N. me Hanson, RK ʻO nā helu kiʻekiʻe o ka moekolohe i ka nui o ka lehulehu: ka hoʻokūkū a me nā mea hōʻike. Hoʻopili i ka wahine Behav. 2006; 35: 37-52

    |

  6. Kraus, SW, Krueger, RB, Briken, P. et al. ʻO ka hana e koi ʻia e hoʻopili ai i ka ICD-11. ʻO ke kaiākamai honua. 2018; 17: 109-110

    |

  7. Goldey, KL a me van Anders, SM ʻO nā manaʻo noʻonoʻo: pili i ka testosterone a me cortisol i nā kāne. Hoʻopili i ka wahine Behav. 2012; 41: 1461-1470

    |

  8. Ragan, PW a me Martin, PR ʻO ka psychobiology o ka hoʻohui wahine. Ka Hoʻoweliweli Pōʻalima. 2000; 7: 161-175

    |

  9. ʻO Ioredane, K., Fromberger, P., Stolpmann, G. et al. ʻO ke kuleana o ka testosterone i ka moekolohe a me ka paraphilia – kahi ala neurobiological. Mahele I: testosterone a me ka moekolohe. ʻO J Sex Med. 2011; 8: 2993-3007

    |

  10. Ciocca, G., Limoncin, E., Carosa, E. et al. He meaʻai ʻo testosterone no ka lolo ?. Sex Med Rev.. 2016; 4: 15-25

    |

  11. ʻO Ioredane, K., Fromberger, P., Stolpmann, G. et al. ʻO ke kuleana o ka testosterone i ka moekolohe a me ka paraphilia – kahi ala neurobiological. Māhele II: testosterone a me paraphilia. ʻO J Sex Med. 2011; 8: 3008-3029

    |

  12. Turner, D. a me Briken, P. Hoʻopilikia i nā maʻi paraphilic i ka lawehala a i ʻole nā ​​kāne me ka loaʻa o ka hōʻeha hewa i ka luteinizing hormone-hoʻokuʻu i nā agonist hormone: kahi loiloi ʻōnaehana hou loa. ʻO J Sex Med. 2018; 15: 77-93

    |

  13. Chatzittofis, A., Arver, S., Öberg, K. et al. HPA axregregation HPA i nā kāne me ka maʻi hypersexual. Psychoneuroendocrinology. 2016; 63: 247-253

    |

  14. Sheehan, DV, Lecrubier, Y., Sheehan, KH et al. ʻO ke kūkākūkā Neuropsychiatric Mini-International (MINI): ka hoʻomohala ʻana a me ka hōʻoia ʻana o ka hālāwai hoʻokūkū diagnostic diagnostic i hoʻonohonoho ʻia no ka DSM-IV a me ICD-10. (quiz 34-57)ʻO J Clin Psychiatry. 1998; 59 Hōʻuluʻulu 20: 22-33

    |

  15. Kalichman, SC a me Rompa, D ʻO ka ʻimi ʻana a me ka hoʻonaninani ʻia ʻo ka moekolohe. J Pers Heluhelu. 1995; 65: 586-601

    |

  16. Svanborg, P. a me Asberg, M. Hoʻohālikelike ma waena o ka waihona Beck depression (BDI) a me ka mana helu o ka Montgomery Asberg depression rating scale (MADRS). J Pili Aloha Ole. 2001; 64: 203-216

    |

  17. Bernstein, DP a me Fink, L. ʻO ka nīnau nīnau no trauma keiki. Ka ʻĀina Pūnaewele, San Antonio, TX; 1998

    |

  18. Jokinen, J., Bostrom, AE, Chatzittofis, A. et al. Methylation o ka HPA axis pili i nā genes i ke kāne me ka maʻi hypersexual. Psychoneuroendocrinology. 2017; 80: 67-73

    |

  19. Stoleru, SG, Ennaji, A., Cournot, A. et al. Hoʻonohonoho ʻia ka LH pulsatile huna a me ka pae koko o ka testosterone e ka ʻuhane pili i nā kāne kāne. Psychoneuroendocrinology. 1993; 18: 205-218

    |

  20. Carosa, E., Benvenga, S., Trimarchi, F. a me al. Hana ka hana maʻamau i ka hoʻololi o ka LH bioavailability. ([kūkākūkā: 100])Ka Int J Komo Kū. 2002; 14: 93-99

    |

  21. Kingston, DA, Seto, MC, Ahmed, AG et al. ʻO ke kuleana o nā hormones kūloko a me peripheral i ka hoʻopili kino a me ka hoʻonaninani i nā kāne lawehala. ʻO J Am Acad Kānāwai Kānāwai. 2012; 40: 476-485

    |

  22. Gaffney, GR a me Berlin, FS Aia aia kekahi hypothalamic-pituitary-gonadal dysfunction ma pedophilia? Ke kumu hoʻokele. Br J Hoʻonaʻauao. 1984; 145: 657-660

    |

  23. Rupp, HA me Wallen, K. ʻO ka pilina ma waena o ka testosterone a me ka makemake i ka hoʻouluʻana i ka wahine: ka hopena o ke ʻike. Horm Behav. 2007; 52: 581-589

    |

  24. Wong, JS a me Gravel, J. Loaʻa i nā lawehala ʻoi aku ka kiʻekiʻe o ka testosterone? Nā hualoaʻa mai kahi meta-analysis. Pelekino Pelekane. 2018; 30: 147-168

    |

  25. Huo, S., Scialli, AR, McGarvey, S. et al. Ke mālama nei no ka kāne no ka "testosterone haʻahaʻa": he loiloi ʻōnaehana PLoS One. 2016; 11: e0162480

    |

  26. Safarinejad, MR Ke mālama nei i ka hypersexuality nonparaphilic i nā kāne me kahi analog mea lōʻihi e hana ana i ka gonadotropin-hoʻokuʻu i ka hormone. ʻO J Sex Med. 2009; 6: 1151-1164

    |

  27. Brown, GR a me Spencer, KA ʻO nā hormone hāmeʻa, ke kaumaha a me ka lolo o ka wā ʻōpio: kahi manaʻo hoʻohālikelike. Neuroscience. 2013; 249: 115-128

    |

  28. Lupien, SJ, McEwen, BS, Gunnar, MR et al. Nā hopena o ke koʻikoʻi ma ke ola o ke olakino ma ka lolo, ka ʻano, a me ka cognition. Nat Rev Neurosci. 2009; 10: 434-445

    |

  29. Dismukes, AR, Johnson, MM, Vitacco, MJ et al. ʻO ka hui ʻana o nā pūlaka HPA a me HPG i ka pōʻaiapili o ka pilikia mua o ke ola i loko o nā ʻōpio kāne incarcerated. ʻO Dev Psychobiol. 2015; 57: 705-718

    |

  30. McEwen, BS, Eiland, L., Hewa, RG et al. Ke kaumaha a me ka hopohopo: hoʻonohonoho plasticity a me ka hoʻoponopono epigenetic ma muli o kahi hopena o ke kaumaha. ʻO Neuropharmacology. 2012; 62: 3-12

    |

  31. Montgomery-Graham, S. Manaʻo a me ka loiloi o ka maʻi hypersexual: kahi loiloi ʻōnaehana o ka palapala. Sex Med Rev.. 2017; 5: 146-162

    |

  32. Mehta, PH, Welker, KM, Zilioli, S. et al. Ka hoʻohālikelike ʻana a me nā testosterone a me cortisol i ka lawe ʻana i ka mālama. Psychoneuroendocrinology. 2015; 56: 88-99

    |

  33. Stefansson, J., Chatzittofis, A., Nordstrom, P. et al. Ua loaʻa ka CSF a me ka testosterone plasma i ka hoʻāʻo ʻana e pepehi. Psychoneuroendocrinology. 2016; 74: 1-6

    |

  34. Raisanen, JC, Chadwick, SB, Michalak, N. et al. ʻO nā hui likeʻole ma waena o ka makemake pilikino, ka testosterone, a me ke kaumaha i loko o nā wahine a me nā kāne i ka wā o ka manawa. Hoʻopili i ka wahine Behav. 2018; 47: 1613-1631

    |

  35. Chadwick, SB, Burke, SM, Goldey, KL et al. Multifaceted makemake makemake a me nā hui pūʻokoʻa: loiloi no ka wahi pilikino, kūlana pilina, a me ka makemake makemake. Hoʻopili i ka wahine Behav. 2017; 46: 2445-2463

    |

  36. Westberg, L. lāua ʻo Eriksson, E. ʻO sex gen pili pili i ka maʻi i loko o nā maʻi psychiatric. ʻO J Psychiatry Neurosci. 2008; 33: 319-330

    |

  37. Comninos, AN a me Dhillo, WS Ke kū nei nā kuleana o kisspeptin i ka hoʻoulu ʻana o ka naʻau a me ke ʻano. Neuroendocrinology. 2018; 106: 195-202

    |

  38. Yang, HP, Wang, L., Han, L. et al. Nā hana Nonsocial o ka hyptalamic hypothalamic. ISRN Neurosci. 2013; 2013: 179272

    |

  39. Jannini, EA, Screponi, E., Carosa, E. et al. ʻO ka hemahema o ka moe kolohe mai ka hanaʻole o ka erectile e pili ana me ka hoʻouka hoʻololi i ka testosterone serum. Int J Androl. 1999; 22: 385-392

    |

Kōkua hihia: Ua komo ʻo Jussi Jokinen i ka Papa Kuhina o Janssen e pili ana i ka esketamine no MDD me ka manaʻo o ka suicidal o kēia manawa me ka manaʻo. ʻO nā mea kākau a pau, hoʻolaha i ka hakakā ʻole o ka hoihoi.

Kākoʻo kālā: ʻO ke kālā kālā no kēia noiʻi ua hāʻawi ʻia e ka ʻĀina noiʻi ʻ Swedishlelo Suwena a me ka Swedish Brain Research Foundation (Helgi B. Schiöth); ma o ka hui kuikahi ma waena o Umeå University a me Västerbotten County Council (ALF); a na nā mea i hāʻawi ʻia e ka ʻaha ʻānō o Stockholm County (ALF) (Jussi Jokinen).